JP2024525897A - 変形性関節症の治療におけるnlrp3阻害剤の投与計画 - Google Patents

変形性関節症の治療におけるnlrp3阻害剤の投与計画 Download PDF

Info

Publication number
JP2024525897A
JP2024525897A JP2024503567A JP2024503567A JP2024525897A JP 2024525897 A JP2024525897 A JP 2024525897A JP 2024503567 A JP2024503567 A JP 2024503567A JP 2024503567 A JP2024503567 A JP 2024503567A JP 2024525897 A JP2024525897 A JP 2024525897A
Authority
JP
Japan
Prior art keywords
compound
use according
subject
nlrp3 inhibitor
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525897A5 (cg-RX-API-DMAC7.html
Inventor
コールマン,ローラ
ファラディー,クリストファー
ガトリック,エヴァ
シーカー,マティアス
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024525897A publication Critical patent/JP2024525897A/ja
Publication of JP2024525897A5 publication Critical patent/JP2024525897A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024503567A 2021-07-23 2022-07-20 変形性関節症の治療におけるnlrp3阻害剤の投与計画 Pending JP2024525897A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163224890P 2021-07-23 2021-07-23
US63/224,890 2021-07-23
PCT/IB2022/056695 WO2023002399A1 (en) 2021-07-23 2022-07-20 Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis

Publications (2)

Publication Number Publication Date
JP2024525897A true JP2024525897A (ja) 2024-07-12
JP2024525897A5 JP2024525897A5 (cg-RX-API-DMAC7.html) 2025-07-28

Family

ID=82846336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503567A Pending JP2024525897A (ja) 2021-07-23 2022-07-20 変形性関節症の治療におけるnlrp3阻害剤の投与計画

Country Status (8)

Country Link
US (1) US20250082611A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373489A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525897A (cg-RX-API-DMAC7.html)
KR (1) KR20240038995A (cg-RX-API-DMAC7.html)
CN (1) CN117693340A (cg-RX-API-DMAC7.html)
CA (1) CA3224774A1 (cg-RX-API-DMAC7.html)
IL (1) IL309085A (cg-RX-API-DMAC7.html)
WO (1) WO2023002399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
JP2021529780A (ja) * 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment

Also Published As

Publication number Publication date
IL309085A (en) 2024-02-01
CN117693340A (zh) 2024-03-12
KR20240038995A (ko) 2024-03-26
EP4373489A1 (en) 2024-05-29
US20250082611A1 (en) 2025-03-13
WO2023002399A1 (en) 2023-01-26
CA3224774A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
US10654816B2 (en) Compounds and compositions for treating conditions associated with NLRP activity
EP3259271B1 (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
US20220339169A1 (en) Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
TWI389689B (zh) 氟利本西林(flibanserin)於治療停經前性慾疾病之用途
NO20171934A1 (en) Compositions and methods of treating a neurodegenerative disease
CN109563088B (zh) MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
EP3681861A1 (en) Cxcr-2 inhibitors for treating disorders
KR20190140011A (ko) 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
JP2018501217A (ja) 統合失調症を治療するための2−((1−(2(4−フルオロフェニル)−2−オキソエチル)ピペリジン−4−イル)メチル)イソインドリン−1−オン
US20200281878A1 (en) Cxcr-2 inhibitors for treating disorders
US20250082611A1 (en) Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis
JP7857235B2 (ja) 慢性腎疾患を処置または防止するための方法
JP2025527188A (ja) Nlrp3阻害剤の投与計画
WO2021079983A1 (ja) 軟骨保護用の医薬組成物
JP2005336174A (ja) 変形性関節症治療剤
US20090156609A1 (en) Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds
JPWO2017119455A1 (ja) 自閉症スペクトラム障害の予防または治療剤
CN121240859A (zh) 用于治疗健康状况的组合物和制备和使用小分子的方法
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
WO2005102332A1 (ja) 変形性関節症治療剤
CN116648445A (zh) 治疗或预防慢性肾脏病的方法
EA042417B1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью nlrp
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250717